NCT05955924View on ClinicalTrials.gov

Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial

PHASE3RecruitingINTERVENTIONAL
Enrollment

396

Participants

Timeline

Start Date

August 28, 2023

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions
Non-melanoma Skin CancerCarcinoma, Squamous CellCarcinoma, Basal CellKeratinocyte Carcinoma
Interventions
DRUG

Nicotinamide

Oral nicotinamide (500 mg) twice daily

DRUG

Placebo

Matching placebo capsule twice daily

Trial Locations (7)

T2N 1N4

NOT_YET_RECRUITING

University of Calgary, Calgary

T6G 2R3

RECRUITING

University of Alberta, Edmonton

V5Z 1M9

RECRUITING

Vancouver General Hospital, Vancouver

V6Z 1Y6

RECRUITING

St. Paul's Hospital, Vancouver

K1Y 4E9

RECRUITING

The Ottawa Hospital, Ottawa

M5G 2C4

RECRUITING

Toronto General Hospital, Toronto

M5S 1B2

RECRUITING

Women's College Hospital, Toronto

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

University Health Network, Toronto

OTHER

collaborator

NOW Foods

OTHER

lead

Women's College Hospital

OTHER